-
公开(公告)号：US20220226383A1
公开(公告)日：2022-07-21
申请号：US17293867
申请日：2019-11-14
Inventor： Joffrey DE LARICHAUDY , Sandy CAZALON NEMORIN
IPC: A61K35/28 , A61K47/26 , A61K47/24 , A61K47/18 , A61K47/22 , A61K47/46 , A61K35/34 , A61K47/12 , A61K9/00
Abstract: Disclosed is a composition including, in a physiologically acceptable medium: a) at least one saccharide; b) at least one vitamin; c) at least one amino acid; d) at least one antioxidant; and e) cells for therapeutic use. The composition has a pH between 7.0 and 8.5, inclusive, and preferably between 7.0 and 8.3. Also disclosed is a method of preserving a sample of cells for therapeutic use, including at least one step of mixing the sample of cells for therapeutic use with the ingredients a) to d) above and a physiologically acceptable medium, the composition that is obtained having a pH between 7.0 and 8.5, inclusive, and preferably between 7.0 and 8.3.
-
公开(公告)号：US20190330369A1
公开(公告)日：2019-10-31
申请号：US16470032
申请日：2017-12-15
Inventor： Abdessatar Sami CHTOUROU , Nathalie FOURNIER , Christophe DE ROMEUF
Abstract: Disclosed is a pharmaceutical composition including, in a pharmaceutically acceptable carrier: a) at least one anti-CD303 antibody; and b) at least one anti-HER2 antibody. Also disclosed is the combination of the two aforementioned antibodies a) and b) to form combination products to be used simultaneously, separately or spread out over a period of time, for the prevention or treatment of HER2-positive cancer.
-
公开(公告)号：US10342734B2
公开(公告)日：2019-07-09
申请号：US15253327
申请日：2016-08-31
Inventor： Priscille Paruit , Brigitte Chaumeton
Abstract: The invention relates to a bag (10) for storing a therapeutic solution, including at least one compartment (11) for receiving a solution and defined by a diaphragm (12). The bag further includes at least one appendage (13) forming an extension of the diaphragm (12) and comprising a writing area (14). The bag for storing a therapeutic solution according to the invention makes it possible to write on the bag with a reduced risk of contamination.
-
公开(公告)号：US20180355034A1
公开(公告)日：2018-12-13
申请号：US15742268
申请日：2016-07-06
Inventor： Philippe Mondon , Céline Monnet-Mars , Alexandre Fontayne , Christophe De Romeuf , Abdessatar Chtourou
CPC classification number: C07K16/283 , A61K39/0008 , A61K39/001 , A61K2039/55 , A61P37/06 , C07K16/00 , C07K2317/52 , C07K2317/70 , C07K2317/94
Abstract: The present invention relates to the use of antibody Fc fragments in the treatment of autoimmune and/or inflammatory diseases, said Fc fragments being isolated recombinant Fc fragments having a modified affinity for at least one of the Fc receptors (FcR), particularly an increased affinity to FcRn.
-
公开(公告)号：US20210214434A1
公开(公告)日：2021-07-15
申请号：US16772244
申请日：2018-12-14
Inventor： Harry MEADE , Céline MONNET , Philippe MONDON
Abstract: Disclosed is a variant of a parent polypeptide including an Fc fragment, the variant having an increased affinity for the FcRn receptor, and an increased affinity for at least one receptor of the Fc fragment (FcR) chosen from the FcγRI (CD64), FcγRIIIa (CD16a) and FcγRIIa (CD32a) receptors, relative to that of the parent polypeptide, characterised in that it includes: (i) the four mutations 334N, 352S, 378V and 397M; and (ii) at least one mutation chosen from 434Y, 434S, 226G, P228L, P228R, 230S, 230T, 230L, 241L, 264E, 307P, 315D, 330V, 362R, 389T and 389K; the numbering being that of the EU index or the Kabat equivalent.
-
Patent Agency Ranking
6.发明申请HIGHLY GALACTOSYLATED ANTI-TNF-ALPHA ANTIBODIES AND USES THEREOF 审中-公开高度抗肿瘤坏死因子-α-ALPHA抗体的抗肿瘤药物及其用途公开(公告)号：US20150368334A1
公开(公告)日：2015-12-24
申请号：US14767117
申请日：2014-02-13
Inventor： Harry M. Meade , Li-How Chen
IPC: C07K16/24
CPC classification number: C07K16/241 , A61K39/39508 , A61K39/3955 , C07K16/04 , C07K16/283 , C07K2317/12 , C07K2317/41 , C07K2317/732 , C07K2317/734 , C07K2317/92
Abstract: In one aspect, the disclosure relates to highly galactosylated anti-TNF-alpha antibodies and compositions thereof. In one aspect, the disclosure relates to populations of anti-TNF-alpha antibodies with a high level of galactosylation, and compositions thereof. In one aspect, the disclosure relates to methods of production and use of highly galactosylated anti-TNF-alpha antibodies and populations of anti-TNF-alpha antibodies with a high level of galactosylation. In some embodiments, the anti-TNF-alpha antibody is adalimumab.
Abstract translation: 一方面，本公开涉及高半乳糖基化抗TNF-α抗体及其组合物。 一方面，本公开涉及具有高水平的半乳糖基化的抗TNF-α抗体群体及其组合物。 一方面，本公开涉及高半乳糖基化抗TNF-α抗体的生产和使用方法以及具有高水平半乳糖基化的抗TNF-α抗体群体。 在一些实施方案中，抗TNF-α抗体是阿达木单抗。
-
公开(公告)号：US20190292269A1
公开(公告)日：2019-09-26
申请号：US16345620
申请日：2017-10-27
Inventor： Céline MONNET
IPC: C07K16/28
Abstract: Disclosed is a variant of a parent polypeptide including an Fc fragment, the variant having an improved half-life with respect to the parent polypeptide, and including at least one mutation of the Fc fragment increasing the binding of Fc to FcRn; and at least one mutation of the Fc fragment increasing the sialylation of Fc.
-
公开(公告)号：US10174110B2
公开(公告)日：2019-01-08
申请号：US14767117
申请日：2014-02-13
Inventor： Harry M. Meade , Li-How Chen
IPC: C07K16/24 , C07K16/04 , A61K39/395 , C07K16/28
Abstract: In one aspect, the disclosure relates to highly galactosylated anti-TNF-alpha antibodies and compositions thereof. In one aspect, the disclosure relates to populations of anti-TNF-alpha antibodies with a high level of galactosylation, and compositions thereof. In one aspect, the disclosure relates to methods of production and use of highly galactosylated anti-TNF-alpha antibodies and populations of anti-TNF-alpha antibodies with a high level of galactosylation. In some embodiments, the anti-TNF-alpha antibody is adalimumab.
-
公开(公告)号：US20170129966A1
公开(公告)日：2017-05-11
申请号：US15315809
申请日：2015-06-02
Inventor： Nicholas C. Masiello
CPC classification number: C07K16/32 , A01K67/0278 , A01K2207/15 , A01K2217/072 , A01K2227/10 , A01K2267/01 , B01D15/30 , B01D15/3809 , B01D15/426 , B01D61/145 , B01D2311/2626 , C07K16/04 , C07K2317/12 , C07K2317/14 , C07K2317/21 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/52 , C07K2317/55 , C07K2317/76 , C07K2317/92 , C12P21/02 , C12Y204/99 , C12Y304/22002
Abstract: In one aspect, the disclosure provides cells and transgenic non-human mammals for the production of Fc fragments, as well as compositions and uses thereof.
-
公开(公告)号：US20200331994A1
公开(公告)日：2020-10-22
申请号：US16697519
申请日：2019-11-27
Inventor： Abdessatar Chtourou
IPC: C07K16/24 , A61K39/395 , A61K31/20
Abstract: The present invention relates to a pharmaceutical composition for oral delivery, including an anti tumour necrosis factor alpha (TNF.alpha.) antibody, preferably a monoclonal antibody produced in the milk of a transgenic non-human animal, and which can be combined advantageously with caprylic acid, and is preferably in a form that is suitable for targeted release of the antibody in the intestine.
-
-
-
-
-
-
-
-
-
Search Results
24
records
(took 0.02 seconds)
